Purigen Biosystems, a Pleasanton, CA-based developer of technology for genomics sample preparation, completed an $18.2M Series A funding.
Backers included 5AM Ventures, Roche Venture Fund and existing investors the Stanford-Startx Fund and Western Investments Capital. Under the terms of the financing, Andy Schwab, Managing Director of 5AM Ventures; Tracy Saxton, Investment Director at Roche Venture Fund; Bill Colston, CEO of HealthTell and former CEO of Quantalife; and Joe Victor, former CEO of DVS Sciences will join Purigen’s Board of Directors.
The company intends to use the funds to accelerate research, development and commercialization of the benchtop technology.
Led by Klint Rose, CEO and Co-Founder, and Amy Hiddessen, CTO, Purigen Biosystems provides an automated benchtop instrumentation and accompanying microfluidic chip that purifies and quantitates nucleic samples from a wide variety of sources, including minute or otherwise challenging cancer samples.
The purified DNA or RNA is then immediately compatible with a wide range of downstream detection methods, including next generation sequencing, PCR, and other genomic tests.